Activation of the NLRP3 inflammasome by cellular labile iron

Experimental Hematology

Volumn 44, Issue 2, 2016, Pages 116-124

  Nakamura, Kyohei ^a,b   Kawakami, Toru ^a   Yamamoto, Naoki ^a   Tomizawa, Miyu ^a   Fujiwara, Tohru ^b   Ishii, Tomonori ^b   Harigae, Hideo ^b   Ogasawara, Kouetsu ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; FERRIC AMMONIUM CITRATE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; IRON; REACTIVE OXYGEN METABOLITE; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; LYSOSOME; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; POTASSIUM TRANSPORT; PRIORITY JOURNAL; ANIMAL; CELL LINE; MOUSE; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; CARRIER PROTEINS; CELL LINE; INTERLEUKIN-1BETA; MICE; REACTIVE OXYGEN SPECIES;

EID: 84957579496     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.11.002     Document Type: Article

References (41)

1. Cazzola M., Bergamaschi G., Dezza L., Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 1990, 75:1903-1919.
2. Brissot P., Ropert M., Le Lan C., Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012, 1820:403-410.
3. Crichton R.R., Wilmet S., Legssyer R., Ward R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002, 91:9-18.
4. Ganz T. Macrophages and systemic iron homeostasis. J Innate Immun 2012, 4:446-453.
5. Aust S.D. Ferritin as a source of iron and protection from iron-induced toxicities. Toxicol Lett 1995, 82/83:941-944.
6. Knutson M.D., Oukka M., Koss M., Aydemir F., Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A 2005, 102:1324-1328.
7. Lee P., Peng H., Gelbart T., Wang L., Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005, 102:1906-1910.
8. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117:4425-4433.
9. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
10. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
11. Rajamaki K., Lappalainen J., Oörni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
12. Vandanmagsar B., Youm Y.H., Ravussin A., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
13. Heneka M.T., Kummer M.P., Stutz A., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674-678.
14. Pétrilli V., Papin S., Dostert C., Mayor A., Martinon F., Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589.
15. Hornung V., Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol 2010, 40:620-623.
16. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
17. Iyer S.S., He Q., Janczy J.R., et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 2013, 39:311-323.
18. Darbari D., Loyevsky M., Gordeuk V., et al. Fluorescence measurements of the labile iron pool of sickle erythrocytes. Blood 2003, 102:357-364.
19. Denes A., Lopez-Castejon G., Brough D. Caspase-1: Is IL-1 just the tip of the ICEberg?. Cell Death Dis 2012, 3:e338.
20. Netea M.G., Nold-Petry C.A., Nold M.F., et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113:2324-2335.
21. Chen G.Y., Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010, 10:826-837.
22. Lamkanfi M., Mueller J.L., Vitari A.C., et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009, 187:61-70.
23. + efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38:1142-1153.
24. Hornung V., Bauernfeind F., Halle A., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
25. Boya P., Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451.
26. Terman A., Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxid Redox Signal 2013, 18:888-898.
27. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 2010, 40:616-619.
28. Dixon S.J., Stockwell B.R. The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014, 10:9-17.
29. Gutierrez J.A., Yu J., Rivera S., Wessling-Resnick M. Functional expression cloning and characterization of SFT, a stimulator of Fe transport. J Cell Biol 1997, 139:895-905.
30. Byrne S.L., Krishnamurthy D., Wessling-Resnick M. Pharmacology of iron transport. Annu Rev Pharmacol Toxicol 2013, 53:17-36.
31. Zhang Z., Zhang F., An P., et al. Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood 2011, 118:1912-1922.
32. Wang L., Harrington L., Trebicka E., et al. Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest 2009, 119:3322-3328.
33. Grant S.M., Wiesinger J.A., Beard J.L., Cantorna M.T. Iron-deficient mice fail to develop autoimmune encephalomyelitis. J Nutr 2003, 133:2635-2638.
34. Baker J.F., Ghio A.J. Iron homoeostasis in rheumatic disease. Rheumatology 2009, 48:1339-1344.
35. Rund D., Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005, 353:1135-1146.
36. Kyriakou D.S., Alexandrakis M., Kyriakou E., et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001, 80:577-583.
37. Pai A.B., Conner T., McQuade C.R., Olp J., Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011, 24:603-613.
38. Fell L.H., Zawada A.M., Rugacev K.S., Seiler S., Fliser D., Heine G.H. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014, 29:809-822.
39. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 2003, 102:2670-2677.
40. Gieling R.G., Wallace K., Han Y.P. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1324-G1331.
41. Artlett C.M. The role of the NLRP3 inflammasome in fibrosis. Open Rheumatol J 2012, 6:80-86.